



Omega Pharma reports on share buy-back programme and announces receipt of two shareholding notifications

Nazareth (Belgium) - 12 September 2011 (6:00 p.m. CET). Omega Pharma (OME BB, OMEP.BR), the specialist in over-the-counter medicines and healthcare products, reports on the status of its share buy-back programme, and announces the receipt of two notifications in accordance with the provisions of the Law of 2 May 2007 on the disclosure of major holdings in listed companies.

Since the decision of the board of directors of Omega Pharma to activate its share buy-back programme for which authorization has been granted by the extraordinary shareholders meeting of 17 June 2011 (cf. press release dd. 2 September 2011), the following numbers of shares have been acquired on NYSE Euronext Brussels through an intermediate, acting with a discretionary mandate:

Date	Number of shares acquired	Average price (in EUR)	Highest price (in EUR)	Lowest price (in EUR)	Total amount (in EUR)
2 September 2011	24,150	35.1951	35.575	34.745	849,961.67
5 September 2011	29,720	34.0276	34.495	33.600	1,011,300.27
6 September 2011	33,973	33.8875	34.110	33.650	1,151,260.04
7 September 2011	33,672	34.4036	34.740	33.700	1,158,438.02
8 September 2011	28,756	34.6362	34.850	34.250	995,998.57
9 September 2011	18,768	34.4782	34.800	34.250	647,086.86
12 September 2011	23,000	34.0011	34.150	33.750	782,025.30
2-12 September 2011	192,039	34.3476	35.575	33.600	6,596,070.72

In addition, and within the same programme and mandate, the following numbers of shares have been acquired in block trades, off exchange:

Date	Number of shares acquired	Price (in EUR)	Total amount (in EUR)
2 September 2011	334,200	35.3200	11,803,944.00
2 September 2011	100,000	34.9000	3,490,000.00
5 September 2011	50,000	34.1200	1,706,000.00
5 September 2011	80,000	34.0000	2,720,000.00
5 September 2011	177,898	34.0000	6,048,532.00
7 September 2011	105,000	34.1000	3,580,500.00
2-12 September 2011	847,098	34.6465	29,348,976.00

Combining both the trades on NYSE Euronext Brussels and the off exchange transactions, a total of 1,039,137 treasury shares have been acquired in the period from 2 to 12 September 2011. Prior to the activation of the programme, Omega Pharma already held 879,994 treasury shares. As a result of the transactions mentioned in the tables above, Omega Pharma now holds 1,919,131 treasury shares, representing 7.92% of the total number of shares outstanding.

Omega Pharma also announces the receipt of two notifications in accordance with the provisions of the Law of 2 May 2007 regarding the disclosure of major shareholding in listed companies:

- 1) Notification of acting in concert, by Marc Coucke, Couckinvest NV, Alychlo NV, Holdco I BE BV, Waterland Private Equity Investments BV. This notification indicates the following:
 - a. On 1 September 2011, Holdco I BE NV, Alychlo NV and Couckinvest NV have entered into an agreement that –subject to the fulfilment of a number of conditions precedent– Holdco I BE NV will become shareholder of Couckinvest NV. In case of entering the capital of Couckinvest NV, Holdco I BE NV will become an important shareholder in Couckinvest NV which would lead to an amendment of the nature of the existing agreement of acting in concert between Couckinvest NV and Marc Coucke in relation to Omega Pharma NV. The (new) agreement of acting in concert does not provide for a direct subscription by Holdco I BE NV or Waterland Private Equity Investments BV of securities issued by Omega Pharma NV.
 - b. Mr Marc Coucke has a direct participation in Omega Pharma. Mr Marc Coucke is also the controlling shareholder, chairman of the board of directors and managing director of Alychlo NV. Alychlo NV is the controlling shareholder of Couckinvest NV, with Couckinvest NV having Mr Marc Coucke as chairman of the board of directors and managing director. Couckinvest NV has a direct participation in Omega

Pharma. Couckinvest NV, Alychlo NV en Holdco I BE NV have entered into an agreement of acting in concert on 1 September 2011. All shares in Holdco I BE NV are owned by Holdco I BE B.V.. All shares in Holdco I BE B.V. are owned by Waterland Private Equity Fund V C.V.. Waterland Private Equity Fund V C.V. is an investment fund managed by Waterland Private Equity Investments B.V.. Omega Pharma is a company controlled by Couckinvest NV.

- 2) Notification of having passed the 35% threshold by Omega Pharma NV, Couckinvest NV, Alychlo NV and Mr Marc Coucke, on 2 September 2011. This notification indicates that Marc Coucke has a direct participation in Omega Pharma, and is the controlling shareholder, chairman of the board of directors and managing director of Alychlo NV, which is in its turn the controlling shareholder of Couckinvest NV, with Mr Marc Coucke as chairman of the board of directors and managing director of Couckinvest NV. Omega Pharma is a company controlled by Couckinvest NV.

Both notifications are available on www.omega-pharma.be under the Investor Relations/News and publications/Transparency information.

Based on the most recently received notifications of all concerned parties, the shareholder structure of Omega Pharma now looks as follows:

Notifying person (date of the most recent notification)	Number of voting rights	Percentage of total
<i>Omega Pharma NV (8 September 2011)</i>	1,338,344	5.52%
<i>Couckinvest NV (8 September 2011)</i>	7,255,501	29.94%
<i>Marc Coucke (8 September 2011)</i>	16,245	0.07%
<i>Alychlo NV (8 September 2011)</i>	0	0.00%
Subtotal	8,610,090	35.53%
Holdco I BE NV*	0	0%
Capital Research and Management Company (11 June 2010)	1,225,543	5.06%
Public	14,396,347	59.41%
Total	24,232,318	100.00%

* Acting in concert with Mr Marc Coucke, Alychlo NV and Couckinvest NV

For more information, please contact

Chris Van Raemdonck (Chris.vanraemdonck@omega-pharma.be)

Investor Relations - Omega Pharma

Direct line: 0032 9 381 0331 - Cell: 0032 499 58 55 31